#ASCO14 - Poster: A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) vs ADT alone in non-metastatic castration-resistant prostate cancer–the SPARTAN trial

CHICAGO, IL USA (UroToday.com) - Presented by Matthew R. Smith,1 Glenn Liu,2 S. Martin Shreeve,3 Shannon Matheny,3 Antonieta Sosa,3 Thian Kheoh,3 Margaret K. Yu,3 and Eric J. Small4 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 ARN-509 smith TPS5100 thumb

1Harvard Medical School and Massachusetts General Hospital Cancer Center, Boston, MA USA
2University of Wisconsin Carbone Cancer Center, Madison, WI USA
3Janssen Research & Development, Los Angeles, CA USA
4University of California San Francisco, San Francisco, CA USA

 

 

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Annual Virtual Meeting / Oct 17
  • 2020 Annual Congress / October 10 - 11
  • 2020 Annual Meeting / October 1-3
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland